U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including http://innovistaconsulting.com/PDF/Innokit/A%20Test%20for%20Safety%20of%20Kitasamycin.pdf

Kitasamycin (INN) is a macrolide antibiotic. It is produced by Streptomyces kitasatoensis. The drug has antimicrobial activity against a wide spectrum of pathogens. Kitasamycin Tartrate In 1953, HATA, et al. reported the isolation of a new antibiotic complex known as kitasamycin (leucomycin). The organism producing this antibiotic complex was obtained from soil samples and named Streptotnyces kitasatoensis HATA. In 1967, eight components were separated and their chemical structures determined. This antibiotic was approved by Ministry of Agriculture in 2001 as the growth promoter additive in poultry and swine to control and prevent digestive and respiratory diseases. Belonging to the macrolide antibiotic, its antibacterial activity is similar to tylosin, erythromycin, spiramycin and oleandomycin. The mode of action is to inhibit the protein synthesis process. Its inhibition spectrum includes Mycoplasmas, Gram-positive bacteria, some Gram-negative bacteria, Leptospira, Rickettsia. It also inhibits most bacteria resistant to penicillin, oxytetracycline, chlortetracycline, erythromycin and chloramphenicol bacteria strains. It is a safe and high efficacy growth-promoting additive for swine and poultry. Although this antibiotic was evaluated many years ago, it was felt of interest to determine its activity against recent isolates of gram-positive cocci. Consequently, the in vitro activity of kitasamycin was determined against 214 gram-positive cocci isolated from clinical specimens. Kitasamycin has activity against the vast majority of clinical isolates of S. aureus, Str. pyogenes and Dipl. pneumoniae, but in vitro studies do not suggest that it has any advantages over currently available antibiotics, although it would be expected to be effective in clinical situations in which erythromycin is indicated.

Originator

Curator's Comment: In 1953, HATA, et al reported the isolation of a new antibiotic complex known as kitasamycin (leucomycin). https://www.jstage.jst.go.jp/article/antibiotics1968/27/7/27_7_516/_pdf

Approval Year

Sample Use Guides

for swine and poultry: fed orally to rats with LD503.8± 0.3 g/kg and mouse with LD50> 8 g/kg. 1500 ppm Kitasamycin inclusion of broiler diets was lasted 10 weeks 500 ppm Kitasamycin in 21 days piglet diets for 6 months
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Mixture
Created
by admin
on Sat Dec 16 07:24:41 UTC 2023
Edited
by admin
on Sat Dec 16 07:24:41 UTC 2023
Record UNII
IPN75MD9DR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KITASAMYCIN TARTRATE
JAN   WHO-DD  
Common Name English
TRUBIN
Brand Name English
Kitasamycin Tartrate [WHO-DD]
Common Name English
KITASAMYCIN TARTRATE [JAN]
Common Name English
LEUCOMYCIN TARTRATE
Common Name English
LEUCOMYCIN, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (SALT)
Common Name English
LEUCOMYCIN, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (SALT)
Common Name English
Code System Code Type Description
FDA UNII
IPN75MD9DR
Created by admin on Sat Dec 16 07:24:41 UTC 2023 , Edited by admin on Sat Dec 16 07:24:41 UTC 2023
PRIMARY
ChEMBL
CHEMBL2106399
Created by admin on Sat Dec 16 07:24:41 UTC 2023 , Edited by admin on Sat Dec 16 07:24:41 UTC 2023
PRIMARY
CAS
37280-56-1
Created by admin on Sat Dec 16 07:24:41 UTC 2023 , Edited by admin on Sat Dec 16 07:24:41 UTC 2023
PRIMARY
EPA CompTox
DTXSID8048604
Created by admin on Sat Dec 16 07:24:41 UTC 2023 , Edited by admin on Sat Dec 16 07:24:41 UTC 2023
PRIMARY
DRUG BANK
DBSALT001604
Created by admin on Sat Dec 16 07:24:41 UTC 2023 , Edited by admin on Sat Dec 16 07:24:41 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Definition References